Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.69 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.50 |
| ▸ | ESR1 | P03372 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8780159 | 0.84 | PSIP1 (0.50) | PTGS2ESR2ESR1ALOX5 | |
| SCHEMBL387063 | 0.83 | ENPP2 (0.61) | PTGS2ENPP2ALOX5 | |
| SCHEMBL5502727 | 0.82 | PTGS2 (1.00) | PTGS2PTGS1 | |
| Hydrogen Sulfide SCHEMBL27744403 | 0.81 | PTGS2 (0.69) | PTGS2PTGS1 | |
| Hydrogen Sulfide SCHEMBL27744400 | 0.81 | PTGS2 (0.96) | PTGS2PTGS1 | |
| SCHEMBL8450699 | 0.80 | ALOX5 (0.68) | ESR2ESR1ALOX5 | |
| SCHEMBL3276100 | 0.80 | ALOX5 (0.68) | ESR2ESR1ALOX5 | |
| Ethane SCHEMBL6838808 | 0.80 | ALOX5 (0.68) | ESR2ESR1ALOX5 | |
| SCHEMBL3802935 | 0.80 | ALOX5 (0.74) | ESR2ESR1ALOX5 | |
| SCHEMBL8442047 | 0.80 | PTGS2 (1.00) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390026-B1 | TREATMENT OF HPV CAUSED DISEASES | CORNELL RES FOUNDATION INC (US) | 2010-05-05 | — | — | EP | claimed |
| EP-1146905-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | Algos Pharmaceutical Corporation (US) | 2001-10-24 | — | — | EP | claimed |
| WO-2000029022-A1 | COX-2 INHIBITORS IN COMBINATION WITH CENTRALLY ACTING ANALGESICS | ALGOS PHARMACEUTICAL CORPORATION (US) | 2000-05-25 | — | — | WO | claimed |
| WO-2000029023-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 2000-05-25 | — | — | WO | claimed |
| WO-1998050075-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
| EP-1039914-A4 | CYCLOOXYGENASE-2 INHIBITION | CORNELL RES FOUNDATION INC (US) | 2007-06-27 | — | — | EP | disclosed |
| EP-1146789-A4 | TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/NEU | CORNELL RES FOUNDATION INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-7041694-B1 | Cyclooxygenase-2 inhibition | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-05-09 | — | — | US | disclosed |
| WO-2005046650-A1 | PHARMACEUTICAL FORMULATION CONTAINING MUSCLE RELAXANT AND COX-II INHIBITOR | GLENMARK PHARMACEUTICALS LIMITED (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050100594-A1 | Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2005-05-12 | — | — | US | disclosed |
| US-20040204413-A1 | Pharmaceutical compositions containing a COX-II inhibitor and a muscle relaxant | OSMOTICA CORP. (VG) | 2004-10-14 | — | — | US | disclosed |
| EP-1109553-A4 | TREATING INFLAMMATORY DISEASES OF THE HEAD AND NECK WITH CYCLOOXYGENASE-2 INHIBITORS | CORNELL RES FOUNDATION INC (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2000029022-A1 | COX-2 INHIBITORS IN COMBINATION WITH CENTRALLY ACTING ANALGESICS | ALGOS PHARMACEUTICAL CORPORATION (US) | 2000-05-25 | — | — | WO | disclosed |
| WO-2000013685-A1 | TREATING INFLAMMATORY DISEASES OF THE HEAD AND NECK WITH CYCLOOXYGENASE-2 INHIBITORS | CORNELL RESEARCH FOUNDATION, INC. (US) | 2000-03-16 | — | — | WO | disclosed |
| EP-0783486-B1 | NOVEL PROSTAGLANDIN SYNTHASE INHIBITORS | DU PONT PHARM CO (US) | 1999-10-13 | — | — | EP | disclosed |
| US-5932586-A | ANTIINFLAMMATORY AGENTS; ANTIPYRETICS | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-08-03 | — | — | US | disclosed |
| WO-1999030721-A1 | CYCLOOXYGENASE-2 INHIBITION | CORNELL RESEARCH FOUNDATION, INC. (US) | 1999-06-24 | — | — | WO | disclosed |
| WO-1998050075-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 1998-11-12 | — | — | WO | disclosed |
| US-5593994-A | ANTIINFLAMMATORY AGENTS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| WO-1996010012-A1 | NOVEL PROSTAGLANDIN SYNTHASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-04-04 | — | — | WO | disclosed |